Engin Ayturk

Senior Director, CMC BioConjugation, Process Development & Manufacturing at Exelixis

Speaker

Engin Ayturk, is a Senior Director at Exelixis and responsible for the development, scale-up and cGMP manufacturing of novel antibody drug conjugate (ADC) technology platforms. Previously at Mersana Therapeutics, Dr. Ayturk led the CMC Process Engineering and BioConjugation departments, also specializing in the development, scale-up and cGMP manufacturing and late-stage characterization and validation of ADC drug-linkers and drug substances. At Biogen, Dr. Ayturk led the Cambridge Process Biochemistry (PBC) small and pilot scale purification and bioseparation development teams and was responsible for the development of purification processes for clinical and commercial biologics programs. During his tenure at Pall Life Sciences, as a Sr. R&D Manager, Dr. Ayturk led the BioPharm Applications R&D Integrated Continuous BioProcessing team and the Filtration Groups for the development and commercialization of next generation novel bioprocess platforms and technologies. In addition to his primary focus on product, process and technology development, characterization, scale-up and tech transfer and cGMP manufacturing, Dr. Ayturk brings a strong emphasis on process modeling, bioprocess economics and the development of process control strategies for various technologies and is well recognized for cross-functional team leadership, internal/external collaborations and partnerships, and CDMO/CMO management and has numerous business certifications on project and people management, agile product development and innovation coaching modules. Dr. Ayturk holds M.Sc. and Ph.D. degrees both in Chemical Engineering and previously worked as a Research Assistant Professor at Worcester Polytechnic Institute (WPI).